{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-23-000091","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2023-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.179024+00:00","generated_at":"2026-06-11T02:08:09.135642+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"JNJ updates 2023 guidance post-Kenvue separation; raises sales & EPS outlook, cuts share count","bullets":["Updated 2023 guidance: Reported Sales Growth 7.0%-8.0%, Adjusted EPS $10.00-$10.10 (12.5% growth at midpoint).","Reduced share count by ~191M shares; partial-year benefit of ~73.5M shares adds $0.28 to EPS.","Received $13.2B cash from Kenvue debt offering and IPO; retains 9.5% equity stake in Kenvue.","Consumer Health now reported as discontinued ops; expects ~$20B gain in Q3 2023.","Maintains quarterly dividend of $1.19/share; H1 2023 continuing ops sales $42.4B (+5.9% total)."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-23-000091","json":"https://secwatch.observer/filing/0000200406-23-000091.json","markdown":"https://secwatch.observer/filing/0000200406-23-000091.md","text":"https://secwatch.observer/filing/0000200406-23-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/0000200406-23-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/jnj-20230830.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:08:09.135642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90d5772ce1d5568f4d70ca08ca08c90693bc7a73","claim":"JOHNSON & JOHNSON updated its guidance (raised).","evidence_excerpt":"Johnson & Johnson completed an exchange offer to finalize the separation of Kenvue Inc. (the \"Kenvue Separation\"). On August 30, 2023, Johnson & Johnson issued the attached press release (Exhibit 99.1) providing updated financials and 2023 guidance following completion of the Kenvue Separation.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000091/0000200406-23-000091-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}